top of page


The Index Committee

The China BioPharma Index is overseen by a committee of advisors who have experience in business and biotechnology. The role of the Committee is to ensure that the index is being managed professionally and according to its stated rules and objectives. Furthermore, the Committee may periodically review the index's methodology, vote on rule changes, and use their industry expertise to determine which stocks qualify to be considered for inclusion. The Committee formally meets before each semi-annual rebalance/reconstitution date, and communicates informally throughout the year as other issues arise. The Committee members are:

Steve Engen - Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 2014, he established his own consultancy, Renegen, and supports biopharma clients including Verastem Oncology. From 2014 until May 2018, Steve was Managing Director and Head of Asia for Locust Walk, where he established the Locust Walk Japan office. Prior to establishing Renegen, Steve headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Purdue’s Japanese subsidiary for nine years. 

Chris Garabedian - Chris Garabedian founded Xontogeny, a biotech aggregator, in June of 2016 and formed a partnership with Perceptive in 2017 to establish the firm’s venture fund strategy. Prior to Xontogeny, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the treatment of Duchenne Muscular Dystrophy. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010 and in a number of global leadership roles at Gilead from 1997 to 2005. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.

Brad Loncar - Owner of Loncar Investments, and founder of The Cancer Immunotherapy Sector Index and The China BioPharma Industry Index. Mr. Loncar is an independent biotechnology industry investor and has managed a biotech-focused family portfolio from his Lenexa, Kansas office since 2008. He previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. Mr. Loncar currently writes biotechnology commentary at and has contributed opinion pieces to Endpoints News and



Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities

bottom of page